Company overview
Basic information
Company name
Construction line, UAB
Company code
306019786
VAT code
LT100015306810
Registered address
Klaipėda, K. Donelaičio g. 19A, LT-92141
Registration date
2022-02-22
Company age: 4 y. 8 mo.
Contact information
Edit data
Phone
Presented as an image – cannot be copied
Email
Presented as an image – cannot be copied
Website
https://constructionline.eu
Company manager
For registered members only
Log in
Indicators
Risk factors
Activity
Legal form
Private Limited Liability Company
NACE activity
New construction
Ownership form
Private without foreign capital
UAB "Construction line"
Company code: 306019786
Address: Klaipėda, K. Donelaičio g. 19A, LT-92141
VAT code: LT100015306810
Description
This description was generated by artificial intelligence.
Construction line, UAB (company code 306019786) is an operational private limited liability company registered in 2022. It is classified as a private company in the national private non-financial sector and is described as privately owned, with more than 50% of authorised capital held by Lithuanian natural and legal persons and no foreign investor capital. Governance is CEO only. The company is based in Klaipeda, Klaipedos city municipality, Klaipeda County, at K. Donelaicio g. 19A. Its main activity is EVRK code F.41.00.10, New construction. In financial year 2025, revenue was €23.16 million, almost unchanged from 2024, while net profit was €443.7 thousand and the profit margin was 1.9%, down from 5.0% in 2024 and 9.6% in 2023. Over two years, revenue increased by 36.3%. Equity stood at €1.64 million and liabilities at €2.25 million. The company is classified as large. Staff data show an average of 316 employees so far in 2026, down from 468 in 2025, while the average monthly wage rose to €1,549.97, up 5.2% year on year and 19.1% over two years.
Download a detailed company report
Make confident decisions with all the information about Construction line, UAB. In one document, you will find full financial data, risk and potential assessment, and key Scoris insights.